Diversity,
Journal Year:
2024,
Volume and Issue:
16(1), P. 30 - 30
Published: Jan. 2, 2024
Klebsiella
oxytoca
is
an
emerging
pathogen
that
can
cause
life-threatening
infectious
diseases
in
humans.
Recently,
we
firstly
reported
for
the
first
time
presence
of
K.
edible
aquatic
animals.
In
this
study,
further
investigated
its
bacterial
environmental
fitness
and
genome
evolution
signatures.
The
results
revealed
isolates
(n
=
8),
originating
from
eight
species
animals,
were
capable
growing
under
a
broad
spectrum
conditions
(pH
4.5–8.5,
0.5–6.5%
NaCl),
with
different
biofilm
formation
swimming
mobility
profiles.
sequences
determined
(5.84–6.02
Mb,
55.07–56.06%
GC
content).
Strikingly,
numerous
putative
mobile
genetic
elements
(MGEs),
particularly
genomic
islands
(GIs,
n
105)
prophages
24),
found
genomes,
which
provided
bacterium
specific
adaptation
traits,
such
as
resistance,
virulence,
material
metabolism.
Interestingly,
identified
prophage-related
clusters
derived
Burkholderia
spp.,
Enterobacter
Pseudomonas
Haemophilus
suggesting
phage
transmission
across
other
four
genera.
Many
strain-specific
10–447)
genes
present
whereas
CRISPR-Cas
protein-encoding
gene
was
absent,
indicating
likely
active
horizontal
transfer
(HGT)
considerable
variation
evolution.
Overall,
study
are
to
demonstrate
compatibility
flexibility
animal
origins.
Frontiers in Microbiology,
Journal Year:
2025,
Volume and Issue:
16
Published: Feb. 27, 2025
Klebsiella
pneumoniae
and
K.
oxytoca
are
members
of
Enterobacteriaceae.
They
Gram-negative,
non-motile
rods
that
ubiquitous
in
the
environment
part
human
intestinal
microbiota.
These
opportunistic
pathogens
may
cause
pneumonia
urinary
tract
infections.
species
genetically
biochemically
similar;
therefore,
it
is
important
to
find
reliable
methods
for
their
differentiation.
This
study
presents
results
biochemical
assays,
PCR,
MALDI-TOF
mass
spectrometry
(MS)
performed
on
35
isolates
obtained
from
urine
patients
central
Poland.
Among
methods,
indole
test
demonstrated
highest
discriminatory
power,
whereas
determination
growth
at
10°C
was
least
effective.
For
all
strains
identified
as
pneumoniae,
a
108-bp
amplicon
detected,
indicating
presence
rpoB
gene
genome.
Only
12
produced
product
pehX
gene.
All
tested
were
analyzed
using
Biotyper,
which
confirmed,
with
high-quality
scores,
identification
based
api
20E
tests.
Strain
0.011
Raoultella
ornithinolytica.
MS
analysis
proved
be
most
method
identifying
potential
phylogroup
Infection Genetics and Evolution,
Journal Year:
2025,
Volume and Issue:
unknown, P. 105740 - 105740
Published: March 1, 2025
Klebsiella
michiganensis,
an
emerging
opportunistic
pathogen,
poses
public
health
risks
due
to
its
increasing
multidrug
resistance
(MDR),
especially
carbapenems.
A
46-year-old
man
with
pulmonary
fibrosis
was
hospitalized
in
Guangzhou,
China,
for
worsening
pneumonia.
multidrug-resistant
K.
michiganensis
strain
(YK6)
isolated
from
his
sputum
before
treatment.
The
characterized
using
MALDI-TOF
mass
spectrometry,
antimicrobial
susceptibility
testing
(AST),
and
whole
genome
sequencing
(WGS).
Targeted
therapy
guided
by
AST
successfully
resolved
the
infection.
YK6
exhibited
carbapenems,
β-lactam/β-lactamase
inhibitors,
cephalosporins,
aminoglycosides,
quinolones,
except
colistin
tigecycline.
Genomic
analysis
revealed
a
41.9-kb
MDR
island
intact
I-E
CRISPR-Cas
system
on
chromosome,
along
two
plasmids:
IncFIA/IncFII
plasmid
pYK6-1
carrying
blaKPC-2
IncC
pYK6-2
harboring
blaVEB-3.
novel
blaKPC-2-transposon
identified,
consisting
of
non-Tn4401
element
(NTE)-like
structure
(Tn3-ISKpn27-blaKPC-2-ΔISKpn6-korC)
flanked
inversely
oriented
ISKpn19-tnpM-tnpR
elements
31-bp
inverted
repeats
never
reported,
configuration
did
not
reported
previously.
Furthermore,
blaVEB-3
genetic
environment
featured
unique
cassette:
IS26-IS6100-blaVEB-3-tnp-ISAs1-qacEΔ1-sul1-ISCR1.
An
additional
ISAs1
insertion
between
tnpF-like
integrase
qacEΔ1
distinguishes
it
similar
blaVEB-3-harboring
cassettes.
region
likely
originated
homologous
recombination
mediated
IS26
Tn5403,
which
flank
gene
cassette.
To
our
knowledge,
this
is
first
report
concurrent
transposon
structure.
These
findings
highlight
urgent
need
enhanced
surveillance
prevent
treatment
failures.
Frontiers in Microbiology,
Journal Year:
2025,
Volume and Issue:
16
Published: March 17, 2025
This
study
isolated
a
Klebsiella
pasteurii
strain,
K1134,
from
the
sputum
of
an
ICU
patient,
revealing
its
resistance
to
carbapenem
antibiotics
meropenem
and
imipenem.
Whole-genome
sequencing
identified
plasmid
pK1134-KPC,
which
carries
gene
bla
KPC-2.
belonging
IncFIIpCP020359
group,
exhibits
modular
structure
with
KPC-2
embedded
in
32.09
kb
accessory
region
containing
multiple
genetic
elements
(AGEs).
Comparative
genomic
analysis
48
K.
isolates
12
countries
showed
high
diversity,
strains
clustered
into
three
clades.
Notably,
harbors
extensive
antimicrobial
genes
across
diverse
AGEs,
classifying
it
as
multidrug-resistant.
Twelve
KPC-carrying
AGEs
were
sequences
isolates,
classified
two
groups:
Tn7551
Tn6296-related
elements.
The
clusters
for
enterotoxins
tilimycin
tilivalline,
encompassing
key
regulators
operons,
present
nearly
all
strains,
incomplete
exclusively
observed
clade
3
isolates.
underscores
global
dissemination
adaptability
pasteurii,
highlighting
potential
role
reservoir
emphasizing
need
robust
surveillance
mitigate
public
health
impact.
Clinical Microbiology Reviews,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 20, 2025
SUMMARYBacillus
Calmette-Guérin
(BCG)
has
been
the
standard
treatment
for
non-muscle-invasive
bladder
cancer
over
30
years.
Despite
its
proven
efficacy,
challenges
persist,
including
unclear
mechanisms
of
action,
resistance
in
30%-50%
patients,
and
significant
side
effects.
This
review
presents
an
updated
balanced
discussion
antitumor
BCG,
focusing
on
direct
effects
interactions
with
various
cell
types
within
tumor
microenvironment.
Notably,
recent
research
between
BCG
microbiome
is
also
incorporated.
We
further
summarize
analyze
latest
preclinical
clinical
studies
regarding
both
intrinsic
adaptive
to
cancer.
Based
current
understanding
BCG's
therapeutic
principles
mechanisms,
we
systematically
explore
strategies
improve
BCG-based
immunotherapy.
These
include
development
recombinant
combination
therapy
different
drugs,
optimization
regimens
management,
exploration
new
approaches
by
targeting
changes
microbiota
metabolites.
measures
aim
effectively
address
cancer,
reduce
toxicity,
ultimately
enhance
anti-tumor
efficacy.
Bacterial
therapy,
represented
genetically
engineered
oncolytic
bacteria,
gradually
emerged
field
As
only
bacterial
drug
successfully
approved
oncology
use,
provided
decades
experience.
By
consolidating
lessons
from
successes
limitations,
hope
provide
valuable
insights
application
therapies
treatment.